Table 1 Putative biomarkers for evaluating anti-TNF therapeutic efficacy in CD patients

• TNFSF4, TNFSF18

rs116724455[C/T]

–

• PLIN2, HAUS6

rs2228416 [T/C]

–

• LTF, CCR5, CCRL2

rs762787 [T/C]

–

• KLHL1

rs9572250 [G/A]

–

• PROX1, RPS6KC1

rs144256942 [G/A]

–

• RORB, TRPM6

rs523781[G/C]

–

• TLR2

rs3804099 [C/T]

–

• TLR2

rs11938228 [C/A]

–

• TLR2

rs1816702 [T/C]

–

• TLR2

rs4696480 [A/T]

–

• TLR4

rs5030728 [G/A]

–

• TLR9

rs352139 [G/A]

–

• NOD2

rs2066844 [C/T]

–

• NOD2

rs2066845 [G/C]

–

• NOD2

rs41450053[C/G]

–

• LY96

rs11465996 [G/C]

–

• IFNG

rs2430561 [A/T]

–

• IL17A

rs2275913 [A/G]

–

Fas ligand

843 CC/TT

–

Caspase-9

93 TT/CC

–

Mucosal transcripts

• TNF-α

–

↑

• IL-17A

–

↑

• OSM

–

↑

• IL-7R^a

–

↑

• miRNAs

–

↑

• TREM1

–

↓

Proteomics

–

↑

Genomic

–

↑